Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice

Journal of Diabetes and its Complications

Volumn 12, Issue 1, 1998, Pages 28-33

  Clements Jr , Rex S ^a   Robison Jr , W Gerald ^b   Cohen, Margo P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED ALBUMIN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; CONTROLLED STUDY; DIABETIC RETINOPATHY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RETINA CAPILLARY; RETINOPATHY;

EID: 0344382052     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(97)00051-2     Document Type: Article

References (46)

1. Klein R, Klein BEK Vision disorders in diabetes. Harris M, Cowie CC, Stern MP, Boyko EJ, Bennett PH Diabetes in America. 1995;293-336 U.S. Government Printing Office (NIH publication no. 95-1468), Bethesda, MD.
2. DCCT Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329:1993;977-986.
3. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 44:1995;968-983.
4. DCCT Research Group The effect of intensive diabetes treatment on progression of diabetic retinopathy in insulin-dependent diabetes mellitus in the Diabetes Control and Complications Trial. Arch Ophthalmol. 113:1995;36-51.
5. DCCT Research Group Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 102:1995;647-661.
6. Bucala R, Cerami A Advanced glycosylation. Chemistry, biology, and implications for diabetes and aging Adv Pharmacol. 23:1992;1-34.
7. Monnier VM, Sell DR, Nagaraj RH, Miyata S, Grandhee S, Odetti P, Ibrahim SA Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging and uremia. Diabetes. 41(suppl 2):1992;36-41.
8. Brownlee M Glycation and diabetic complications. Diabetes. 43:1994;836-841.
9. Bucala R, Cerami A, Vlassara H Advanced glycosylation end products in diabetic complications. Biochemical basis and prospects for therapeutic intervention Diabetes Rev. 3:1995;258-268.
10. Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Smith J, Brinck-Johnsen T, Bucala R, Vlassara H Formation of immunochemical advanced glycation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes. 44:1995;824-829.
11. Cohen MP, Ziyadeh FN Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy. J Am Soc Nephrol. 7:1996;183-190.
12. Guthrow CE, Morris MA, Day JF, Thorpe SR, Baynes J Enhanced nonenzymatical glucosylation of serum albumin in diabetes mellitus. Proc Natl Acad Sci USA. 76:1979;4258-4261.
13. Dolhofer R, Wieland OH Increased glycosylation of serum albumin in diabetes mellitus. Diabetes. 29:1980;417-422.
14. Day JF, Ingelbretsen CG, Ingelbretsen WR, Baynes JW, Thorpe SR Nonenzymatic glucosylation of serum proteins and hemoglobin. Response to changes in blood glucose levels in diabetic rats Diabetes. 29:1980;524-527.
15. Schleicher ED, Gerbitz KD, Dolhofer R, Reindl E, Weiland OH, Edelmann E, Haslbeck M, Kemmler W, Walter H, Mehnert H Clinical utility of nonenzymatically glycosylated blood proteins as an index of glucose control. Diabetes Care. 7:1984;548-556.
16. Cohen MP, Hud E Measurement of plasma glycoalbumin levels with a monoclonal antibody based ELISA. J Immunol Meth. 122:1989;279-283.
17. Hud E, Cohen MP Evaluation and performance characteristics of a novel ELISA using monoclonal antibody to glycated albumin. Clin Chim Acta. 185:1989;157-164.
18. Schleicher E, Wieland OH Protein glycation. Measurement and clinical relevance Clin Chem Clin Biochem. 27:1989;577-587.
19. 1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care. 18:1995;440-447.
20. Ziyadeh FN, Cohen MP Effects of glycated albumin on mesangial cells. Evidence for a role in diabetic nephropathy Mol Cell Biochem. 125:1993;19-25.
21. Cohen MP, Ziyadeh FN Amadori glucose adducts modulate mesangial cell growth and collagen gene expression. Kidney Int. 45:1994;475-484.
22. Cohen MP, Hud E, Wu VY, Ziyadeh FN Albumin modified by Amadori glucose adducts activates mesangial cell type IV collagen gene transcription. Mol Cell Biochem. 151:1995;61-67.
23. Cohen MP, Hud E, Wu VY Amelioration of diabetic nephropathy with monoclonal antibodies against glycated albumin. Kidney Int. 45:1994;1673-1679.
24. Cohen MP, Sharma K, Jin Y, Hud E, Wu VY, Tomaszewski J, Ziyadeh FN Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy J Clin Invest. 95:1995;2338-2345.
25. Cohen MP, Clements RS, Cohen JA, Shearman CW Prevention of decline in renal function in the diabetic db/db mouse. Diabetologia. 39:1996;270-274.
26. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz FC Structural functional relationships in diabetic nephropathy. J Clin Invest. 74:1984;1143-1155.
27. Osterby R, Parving HH, Hommel E, Jorgensen HE, Lokkegard H Glomerular structure and function in diabetic nephropathy. Early to advanced stages Diabetes. 39:1990;1057-1063.
28. Steffes MW, Bilous RW, Sutherland DER, Mauer SM Cell and matrix components of the glomerular mesangium in type I diabetes. Diabetes. 41:1992;679-684.
29. Cohen MP, Clements RS, Hud E, Cohen JA, Ziyadeh FN Evolution of renal function abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy. Exp Nephrol. 4:1996;166-171.
30. Like AA, Lavine RL, Poffenbarger PL, Chick WL Studies in the diabetic mutant mouse. Am J Pathol. 66:1972;193-204.
31. Lee SM, Graham A Early immunopathologic events in experimental diabetic nephropathy. A study in db/db mice Exp Mol Pathol. 33:1980;323-332.
32. Lee SM, Bressler R Prevention of diabetic nephropathy by diet control in the db/db mouse. Diabetes. 30:1981;106-111.
33. Li W, Shen S, Khatami M, Rockey JH Stimulation of retinal capillary pericyte protein and collagen synthesis in culture by high-glucose concentration. Diabetes. 33:1984;785-789.
34. Chibber R, Molinatti PA, Wong JSK, Mirlees D, Kohner EM The effect of aminoguanidine and tolrestat on glucose toxicity in bovine retinal capillary pericytes. Diabetes. 43:1994;758-763.
35. Yamagishi S, Hsu C, Taniguchi M, Harada S, Yamamoto Y, Ohs K, Kobayashi K, Yamamoto H Receptor-mediated toxicity to pericytes of advanced glycosylation end products. Biochem Biophys Res Commun. 213:1995;681-687.
36. Krantz S, Brandt R, Gromoll B Binding sites for short term glycated albumin on peritoneal cells of the rat. Biochim Biophys Acta. 1177:1993;15-24.
37. Midena E, Segato R, Radin S, De Giorgio G, Meneghini F, Piermorocchi S, Belloni AS Studies on the retina of the diabetic db/db mouse. 1. Endothelial cell-pericyte ratio Ophthalmic Res. 21:1989;106-111.
38. Cohen MP, Hud E Production and characterization of monoclonal antibodies against human glycoalbumin. J Immunol Meth. 117:1989;121-129.
39. National Institutes of Health National Institutes of Health guide for the care and use of laboratory animals. 1985;U.S. Government Printing Office (NIH publication no. 85-23 revised), Bethesda, MD.
40. Yanoff M Ocular pathology of diabetes mellitus. Am J Ophthalmol. 67:1969;21-38.
41. Ashton N Pathogenesis of diabetic retinopathy. Little HL, Jack RL, Patz A, Forsham PH Diabetic Retinopathy. 1983;593-640 Thieme-Stratton, New York.
42. Hammes H-P, Martin IS, Federlin K, Geisen K, Brownlee M Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA. 88:1991;11555-11558.
43. Edelstein D, Brownlee M Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes. 41:1992;26-29.
44. Robison WG, Laver NM, Lou MF The role of aldose reductase in diabetic retinopathy. Prevention and intervention studies Osborne NN, Chader GJ Progress in Retinal and Eye Research vol 14. 1995;593-640 Pergamon, Oxford.
45. Robison WG, Kador PE, Kinoshita JH Retinal capillaries. Basement membrane thickening by galactosemia prevented with aldose reductase inhibitor Science. 221:1983;1177-1179.
46. Nyengaard JR, Chang K, Berhorst S, Reiser KM, Williamson JR, Tilton RG Discordant effects on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats. Diabetes. 46:1997;94-106.